News

Sanofi raises forecast for 2016

Saturday 29 October 2016
Country
France

Strong demand for rare disease medicines and early shipments of influenza vaccines to the US boosted third-quarter sales at Sanofi SA, offsetting the loss of income from the off-patent insulin Lantus. As a result, Sanofi upgraded its profit forecast for 2016.

Partial hold on AZ’s durvalumab

Friday 28 October 2016
Country
United Kingdom

Recruitment for Phase 3 clinical trials of AstraZeneca’s treatment for head and neck cancer, both mono and combination therapies, has been suspended by the US regulator because of bleeding by some of the patients, the UK company disclosed on 27 October.

Novartis drives productivity

Friday 28 October 2016
Country
Switzerland

Novartis’ management continued to implement measures to improve productivity in the third quarter as the company faced generic competition for the oncology drug Gleevec, and sales of its Alcon eye division declined.

New Swiss biotech launched

Thursday 27 October 2016
Country
Switzerland

A new Swiss biotech company, Inositec AG, has been launched with seed capital of CHF1.4 million ($1.42 million) to advance a drug candidate into the clinic using a new small molecule technology developed by researchers at ETH Zurich.

GSK reports broadly-based growth

Wednesday 26 October 2016
Country
United Kingdom

GlaxoSmithKline Plc reported higher revenue across its three main businesses in the third quarter, including a rise in sales for new respiratory products. This more than offset declines for Advair, the company’s off-patent asthma medicine.

Evotec is acquiring Cyprotex

Wednesday 26 October 2016
Country
Germany

Evotec AG, which operates a global drug discovery business, is proposing to acquire Cyprotex Plc, a London-listed contract research organisation, which has developed a service for measuring the performance of drugs under development called ADME-Tox.

Roche reports higher nine-month sales

Thursday 20 October 2016
Country
Switzerland

  Roche Holding AG said that its sales rose 4.0% in the first nine months to CHF 37.5 billion (€34.59 billion), measured at constant exchange rates, compared with a 6% gain in the previous nine month period.

Crispr Therapeutics raises funds in US and Europe

Wednesday 19 October 2016
Country
Switzerland

 Crispr Therapeutics AG, which is preparing nine gene-edited projects for clinical testing, has raised $91 million with an initial public offering (IPO) of shares on the Nasdaq market in the US and a private placement in Europe.

Explaining cancer risk

Tuesday 18 October 2016
Country
Netherlands

Research carried out in the Netherlands shows that a person’s risk of getting cancer cannot be explained by the number of errors found in DNA. Scientists at the University Medical Center Utrecht and the Hubrecht Institute have come to this conclusion after mapping the genetic profile of organoids.

New drug for liver disease

Friday 14 October 2016
Country
United Kingdom

A new medicine that is expected to protect against a rare liver disease known as primary biliary cholangitis, has been recommended for approval in the European Union following a Phase 3 study in which the treatment showed a clear benefit over placebo.